Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance Mechanism
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Aggregation of the small peptide amyloid beta (Aβ) into oligomers and fibrils in the brain is believed to be a precursor to Alzheimer’s disease. Aβ is produced via multiple proteolytic cleavages of amyloid precursor protein (APP), mediated by the enzymes β- and γ-secretase. In this study, we examine the temporal dynamics of soluble (unaggregated) Aβ in the plasma and cerebral-spinal fluid (CSF) of rhesus monkeys treated with different oral doses of a γ-secretase inhibitor. A dose-dependent reduction of Aβ concentration was observed within hours of drug ingestion, for all doses tested. Aβ concentration in the CSF returned to its predrug level over the monitoring period. In contrast, Aβ concentration in the plasma exhibited an unexpected overshoot to as high as 200% of the predrug concentration, and this overshoot persisted as late as 72 hours post-drug ingestion. To account for these observations, we proposed and analyzed a minimal physiological model for Aβ dynamics that could fit the data. Our analysis suggests that the overshoot arises from the attenuation of an Aβ clearance mechanism, possibly due to the inhibitor. Our model predicts that the efficacy of Aβ clearance recovers to its basal (pretreatment) value with a characteristic time of >48 hours, matching the time-scale of the overshoot. These results point to the need for a more detailed investigation of soluble Aβ clearance mechanisms and their interaction with Aβ-reducing drugs.
- Craft, D.L., Wein, L.M., Selkoe, D.J., 2002. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer’s brain, CSF and plasma. Bull. Math. Biol. 64, 1011–1031. CrossRef
- Deane, R., Yan, S. Du, Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A.M., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907–913. CrossRef
- Efron, B., Tibshirani, R.J., 1994. An Introduction to the Bootstrap. Chapman and Hall, London.
- Evans, D.A., Funkenstein, H.H., Albert, M.S., Scherr, P.A., Cook, N.R., Chown, M.J., Hebert, L.E., Hennekens, C.H., Taylor, J.O., 1989. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262, 2551–2556. CrossRef
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., Frangione, B., 2004. Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J. Biol. Chem. 279, 45897–45908. CrossRef
- Gilberto, D.B., Zeoli, A.H., Szczerba, P.J., Gehret, J.R., Holahan, M.A., Sitko, G.R., Johnson, C.A., Cook, J.J., Motzel, S.L., 2003. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp. Top. Lab. Anim. Sci. 42, 53–59.
- Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356. CrossRef
- Hardy, J.A., Higgins, G.A., 1992. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185. CrossRef
- Kandimalla, K.K., Curran, G.L., Holasek, S.S., Gilles, E.J., Wengenack, T.M., Poduslo, J.F., 2005. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer’s disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313, 1370–1378. CrossRef
- Lundkvist, J., Naslund, J., 2007. Gamma-secretase: a complex target for Alzheimer’s disease. Curr. Opin. Pharmacol. 7, 112–118. CrossRef
- Mackic, J.B., Bading, J., Ghiso, J., Walker, L., Wisniewski, T., Frangione, B., Zlokovic, B.V., 2002. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer’s disease lesions. Vascul. Pharmacol. 38, 303–313. CrossRef
- Nachbar, R.B., Pak, I., Spann, A., 2006. Kinetic models in biology and chemistry. Wolfram Technology Conference. URL http://library.wolfram.com/infocenter/Conferences/6463/.
- Rosen, L.B., Stone, J.A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al., 2006. The gamma-secretase inhibitor mk-0752 acutely and significantly reduces csf ab40 concentrations in humans. In: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid. Abstract 04-03-02.
- Selkoe, D.J., Schenk, D., 2003. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584. CrossRef
- Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, D.M., Miller, C.A., Strickland, D.K., Ghiso, J., Zlokovic, B.V., 2000. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489–1499. CrossRef
- Siemers, E., Skinner, M., Dean, R.A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., May, P.C., 2005. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126–132. CrossRef
- Siemers, E.R., Quinn, J.F., Kaye, J., Farlow, M.R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J.E., Holtzman, D.M., Knopman, D.S., Satterwhite, J., Gonzales, C., Dean, R.A., May, P.C., 2006. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602–604. CrossRef
- Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., Terasaki, T., 2006. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm. Res. 23, 1407–1416. CrossRef
- Tanzi, R.E., Moir, R.D., Wagner, S.L., 2004. Clearance of Alzheimer’s Abeta peptide: the many roads to perdition. Neuron 43, 605–608.
- Tian, G., Sobotka-Briner, C.D., Zysk, J., Liu, X., Birr, C., Sylvester, M.A., Edwards, P.D., Scott, C.D., Greenberg, B.D., 2002. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J. Biol. Chem. 277, 31499–31505. CrossRef
- Zlokovic, B.V., 2004. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89, 807–811. CrossRef
- Zlokovic, B.V., Yamada, S., Holtzman, D., Ghiso, J., Frangione, B., 2000. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6, 718. CrossRef
- Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance Mechanism
Bulletin of Mathematical Biology
Volume 73, Issue 1 , pp 230-247
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- γ-secretase inhibitor
- Amyloid-β clearance
- Industry Sectors
- Author Affiliations
- 1. Department of Mathematics, University of British Columbia, 1984 Mathematics Road, Vancouver, BC, V6T 1Z2, Canada
- 2. Department of Microbiology and Immunology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada
- 3. Applied Computer Science and Mathematics Department, Merck Research Laboratories, 126 E. Lincoln Ave., Rahway, NJ, 07065, USA
- 4. Department of Alzheimer’s Research, Merck Research Laboratories, PO Box 4, West Point, PA, 19486, USA
- 5. Imaging Research Department, Merck Research Laboratories, PO Box 4, West Point, PA, 19486, USA